Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Montemurro, Filippo; Prat, Aleix; Rossi, Valentina; Valabrega, Giorgio; Sperinde, Jeff; Peraldo-Neia, Caterina; Donadio, Michela; Galván, Patricia; Sapino, Anna; Aglietta, Massimo; Baselga, José; Scaltriti, Maurizio

Montemurro, Filippo; Prat, Aleix; Rossi, Valentina; Valabrega, Giorgio; Sperinde, Jeff; Peraldo-Neia, Caterina; Donadio, Michela; Galván, Patricia; Sapino, Anna; Aglietta, Massimo; Baselga, José; Scaltriti, Maurizio.

Montemurro F; Unit of Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia, Institute of Candiolo (IRCCs), Str. Provinciale 142, 10060 Candiolo, Italy; Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia, Institute of Candiolo (IRCCs), Str. Provinciale 142, 10060 Candi
Prat A; Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Rossi V; Unit of Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia, Institute of Candiolo (IRCCs), Str. Provinciale 142, 10060 Candiolo, Italy.
Valabrega G; Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia, Institute of Candiolo (IRCCs), Str. Provinciale 142, 10060 Candiolo, Italy.
Sperinde J; Clinical Research, Monogram Biosciences, Inc., 345 Oyster Point Blvd., South San Francisco, CA, USA.
Peraldo-Neia C; Laboratory of Cell Therapy, Fondazione del Piemonte per l'Oncologia, Institute of Candiolo (IRCCs), Candiolo, Italy.
Donadio M; A.O. Città della Salute e della Scienza di Torino - sede Molinette, C.so Bramante 88/90, 10126 Torino, Italy.
Galván P; Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Sapino A; Department of Biological Sciences and Human Oncology, Universita di Torino, Str. Provinciale 142, 10060 Candiolo, Italy.
Aglietta M; Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia, Institute of Candiolo (IRCCs), Str. Provinciale 142, 10060 Candiolo, Italy.
Baselga J; Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA.
Scaltriti M; Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Electronic address: scaltrim@mskcc.org.

Mol Oncol ; 8(1): 20-6, 2014 Feb.

Article en En | MEDLINE | ID: mdl-24075779

Asunto(s)

Anticuerpos Monoclonales Humanizados/uso terapéutico; Antineoplásicos/uso terapéutico; Neoplasias de la Mama/tratamiento farmacológico; Quinazolinas/uso terapéutico; Receptor ErbB-2/genética; Adulto; Anciano; Neoplasias de la Mama/diagnóstico; Neoplasias de la Mama/genética; Supervivencia sin Enfermedad; Femenino; Humanos; Estimación de Kaplan-Meier; Lapatinib; Persona de Mediana Edad; Pronóstico; Estudios Prospectivos; Transcriptoma; Trastuzumab; Resultado del Tratamiento

Palabras clave

(H2T); (p95); CR; CT; Chemotherapy-free; HER2-enriched; Lapatinib; MR; Microarray; OS; PD; PFS; PP; PR; ROR; SD; Signature; Trastuzumab; chemotherapy; complete remission; minimal response; overall survival; p95HER2; partial remission; persistence on protocol; progression-free survival; progressive disease; risk of relapse; stable disease; total HER2

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinazolinas / Neoplasias de la Mama / Receptor ErbB-2 / Anticuerpos Monoclonales Humanizados / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Año: 2014 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google